Skip to main content
Top
Published in: Addiction Science & Clinical Practice 1/2021

Open Access 01-12-2021 | Addiction | Research

Facilitating rapid access to addiction treatment: a randomized controlled trial

Authors: Anita Srivastava, Sarah Clarke, Kate Hardy, Meldon Kahan

Published in: Addiction Science & Clinical Practice | Issue 1/2021

Login to get access

Abstract

Background

Obtaining timely access to addiction medicine treatment for patients with substance use disorders is challenging and patients often have to navigate complex referral pathways. This randomized controlled trial examines the effect of providing an expedited pathway to addiction medicine treatment on initial treatment engagement and health care utilization.

Methods

Individuals with possible alcohol or opioid use disorder were recruited from three residential withdrawal management services (WMS). Subjects randomized to the Delayed Intervention (DI) group were given contact information for a nearby addiction medicine clinic; those randomized to the Rapid Intervention (RI) group were given an appointment at the clinic within 2 days and were accompanied to their first appointment.

Results

Of the 174 individuals who were screened, 106 were randomized to either the DI or RI group. The two groups were similar in demographics, housing status, and substance use in the last 30 days. In the 6-month period following randomization, 85% of the RI group attended at least one clinic appointment, compared to only 29% in the DI group (p < 0.0001). The RI group had a mean of 6.39 ED visits per subject in the 12 months after randomization, while the DI group had a mean of 13.02 ED visits per subject in the same 12-month period (p = 0.0469). Other health utilization measures did not differ between the two groups.

Conclusion

Providing immediate facilitated access to an addiction medicine service resulted in greater initial engagement and reduced emergency department visits at 6 months.
Trial registration This trial is registered at the National Institutes of Health (ClinicalTrials.gov) under identifier #NCT01934751.
Appendix
Available only for authorised users
Footnotes
1
Extended-release intramuscular naltrexone is currently not available in Canada.
 
2
The non-clinical research assistant was not qualified to diagnose participants with AUD or OUD. The investigators determined that these screening tools were adequate to identify possible use disorders. The diagnosis was confirmed (without any disparities found) by medical staff using standard DSM criteria upon admission to the medical hospital-based program.
 
Literature
2.
go back to reference Snyder JL, Bowers T. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials. Am J Drug Alcohol Abuse. 2008;34(4):449–61.CrossRef Snyder JL, Bowers T. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials. Am J Drug Alcohol Abuse. 2008;34(4):449–61.CrossRef
3.
go back to reference Rosner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol. 2008;22(1):11–23.CrossRef Rosner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol. 2008;22(1):11–23.CrossRef
4.
go back to reference Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.
5.
go back to reference Spithoff S, Turner S, Gomes T, Martins D, Singh S. First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario. Can Fam Physician. 2017;63(5):e277-83.PubMedPubMedCentral Spithoff S, Turner S, Gomes T, Martins D, Singh S. First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario. Can Fam Physician. 2017;63(5):e277-83.PubMedPubMedCentral
6.
go back to reference Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1–7.CrossRef Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1–7.CrossRef
7.
go back to reference Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–6.CrossRef Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–6.CrossRef
8.
go back to reference D’Onofrio G, O’Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636–44.CrossRef D’Onofrio G, O’Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636–44.CrossRef
9.
go back to reference Srivastava A, Kahan M, Njoroge I, Sommer LZ. Buprenorphine in the emergency department: Randomized clinical controlled trial of clonidine versus buprenorphine for the treatment of opioid withdrawal. Can Fam Physician. 2019;65(5):e214-20.PubMedPubMedCentral Srivastava A, Kahan M, Njoroge I, Sommer LZ. Buprenorphine in the emergency department: Randomized clinical controlled trial of clonidine versus buprenorphine for the treatment of opioid withdrawal. Can Fam Physician. 2019;65(5):e214-20.PubMedPubMedCentral
10.
go back to reference Kim JJ, Kwok ESH, Cook OG, Calder LA. Characterizing highly frequent users of a large canadian urban emergency department. West J Emerg Med. 2018;19(6):926–33.CrossRef Kim JJ, Kwok ESH, Cook OG, Calder LA. Characterizing highly frequent users of a large canadian urban emergency department. West J Emerg Med. 2018;19(6):926–33.CrossRef
11.
go back to reference Haley SJ, Dugosh KL, Lynch KG. Performance contracting to engage detoxification-only patients into continued rehabilitation. J Subst Abuse Treat. 2011;40(2):123–31.CrossRef Haley SJ, Dugosh KL, Lynch KG. Performance contracting to engage detoxification-only patients into continued rehabilitation. J Subst Abuse Treat. 2011;40(2):123–31.CrossRef
12.
go back to reference McLellan AT, Weinstein RL, Shen Q, Kendig C, Levine M. Improving continuity of care in a public addiction treatment system with clinical case management. Am J Addict. 2005;14(5):426–40.CrossRef McLellan AT, Weinstein RL, Shen Q, Kendig C, Levine M. Improving continuity of care in a public addiction treatment system with clinical case management. Am J Addict. 2005;14(5):426–40.CrossRef
13.
go back to reference Hoffman KA, Ford JH, Tillotson CJ, Choi D, McCarty D. Days to treatment and early retention among patients in treatment for alcohol and drug disorders. Addict Behav. 2011;36(6):643–7.CrossRef Hoffman KA, Ford JH, Tillotson CJ, Choi D, McCarty D. Days to treatment and early retention among patients in treatment for alcohol and drug disorders. Addict Behav. 2011;36(6):643–7.CrossRef
15.
go back to reference Palepu A, Gadermann A, Hubley A, Farrell S, Gogosis E, Aubry T, et al. Substance use and access to health care and addiction treatment among homeless and vulnerably housed persons in three Canadian cities. PLoS ONE. 2013;8:e75133.CrossRef Palepu A, Gadermann A, Hubley A, Farrell S, Gogosis E, Aubry T, et al. Substance use and access to health care and addiction treatment among homeless and vulnerably housed persons in three Canadian cities. PLoS ONE. 2013;8:e75133.CrossRef
16.
go back to reference Redko C, Rapp RC, Carlson RG. Waiting time as a barrier to treatment entry: perceptions of substance users. J Drug Issues. 2006;36(4):831–52.CrossRef Redko C, Rapp RC, Carlson RG. Waiting time as a barrier to treatment entry: perceptions of substance users. J Drug Issues. 2006;36(4):831–52.CrossRef
17.
go back to reference Pollini RA, McCall L, Mehta SH, Vlahov D, Strathdee SA. Non-fatal overdose and subsequent drug treatment among injection drug users. Drug Alcohol Depend. 2006;83(2):104–10.CrossRef Pollini RA, McCall L, Mehta SH, Vlahov D, Strathdee SA. Non-fatal overdose and subsequent drug treatment among injection drug users. Drug Alcohol Depend. 2006;83(2):104–10.CrossRef
19.
go back to reference Moehring A, Rumpf H-J, Hapke U, Bischof G, John U, Meyer C. Diagnostic performance of the alcohol use disorders identification test (AUDIT) in detecting DSM-5 alcohol use disorders in the general population. Drug Alcohol Depend. 2019;204:107530.CrossRef Moehring A, Rumpf H-J, Hapke U, Bischof G, John U, Meyer C. Diagnostic performance of the alcohol use disorders identification test (AUDIT) in detecting DSM-5 alcohol use disorders in the general population. Drug Alcohol Depend. 2019;204:107530.CrossRef
20.
go back to reference Lo-Ciganic W-H, Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, Cathers T, et al. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2016;111(5):892–902.CrossRef Lo-Ciganic W-H, Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, Cathers T, et al. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2016;111(5):892–902.CrossRef
21.
go back to reference Busch SH, Fiellin DA, Chawarski MC, Owens PH, Pantalon MV, Hawk K, et al. Cost-effectiveness of emergency department-initiated treatment for opioid dependence. Addiction. 2017;112(11):2002–10.CrossRef Busch SH, Fiellin DA, Chawarski MC, Owens PH, Pantalon MV, Hawk K, et al. Cost-effectiveness of emergency department-initiated treatment for opioid dependence. Addiction. 2017;112(11):2002–10.CrossRef
22.
go back to reference Holzbach R, Stammen G, Kirchhof U, Scherbaum N. The Prescription of anticraving medication and its economic consequences. Eur Addict Res. 2019;25(5):224–8.CrossRef Holzbach R, Stammen G, Kirchhof U, Scherbaum N. The Prescription of anticraving medication and its economic consequences. Eur Addict Res. 2019;25(5):224–8.CrossRef
23.
go back to reference Baser O, Chalk M, Rawson R, Gastfriend DR. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence. Am J Manag Care. 2011;17(Suppl 8):S222-34.PubMed Baser O, Chalk M, Rawson R, Gastfriend DR. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence. Am J Manag Care. 2011;17(Suppl 8):S222-34.PubMed
24.
go back to reference Schwarz R, Zelenev A, Bruce RD, Altice FL. Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. J Subst Abuse Treat. 2012;43(4):451–7.CrossRef Schwarz R, Zelenev A, Bruce RD, Altice FL. Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. J Subst Abuse Treat. 2012;43(4):451–7.CrossRef
25.
go back to reference Wiercigroch D, Sheikh H, Hulme J. A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use. Subst Abuse Treat Prev Policy. 2020;15(1):4.CrossRef Wiercigroch D, Sheikh H, Hulme J. A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use. Subst Abuse Treat Prev Policy. 2020;15(1):4.CrossRef
26.
go back to reference Corace K, Willows M, Schubert N, Overington L, Mattingly S, Clark E, et al. Alcohol medical intervention clinic: a rapid access addiction medicine model reduces emergency department visits. J Addict Med. 2020;14(2):163–71.CrossRef Corace K, Willows M, Schubert N, Overington L, Mattingly S, Clark E, et al. Alcohol medical intervention clinic: a rapid access addiction medicine model reduces emergency department visits. J Addict Med. 2020;14(2):163–71.CrossRef
27.
go back to reference Hu T, Snider-Adler M, Nijmeh L, Pyle A. Buprenorphine/naloxone induction in a Canadian emergency department with rapid access to community-based addictions providers. CJEM. 2019;21(4):492–8.CrossRef Hu T, Snider-Adler M, Nijmeh L, Pyle A. Buprenorphine/naloxone induction in a Canadian emergency department with rapid access to community-based addictions providers. CJEM. 2019;21(4):492–8.CrossRef
Metadata
Title
Facilitating rapid access to addiction treatment: a randomized controlled trial
Authors
Anita Srivastava
Sarah Clarke
Kate Hardy
Meldon Kahan
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Addiction Science & Clinical Practice / Issue 1/2021
Electronic ISSN: 1940-0640
DOI
https://doi.org/10.1186/s13722-021-00240-y

Other articles of this Issue 1/2021

Addiction Science & Clinical Practice 1/2021 Go to the issue